Complex Innovative Design trials podcast series
This podcast series supports effective trial planning and design of Complex Innovative Design (CID) trials.
About the podcast series
These podcasts provide information and guidance useful for anyone with an interest in working on or reviewing CID trials. They are presented by an experienced researcher, patient representative, statistician, ethics committee chair and member of the Health Research Authority (HRA).
Some of the podcasts in the series were developed jointly with the HRA and some have been provided by the The National Institute for Health Research (NIHR). We created this joint playlist to support delivery of the recommendations from our consensus paper on CID trials.
Podcast episodes
Discussion on the definition of CID trials
Emma Lowe, Department of Health and Social Care (DHSC), discusses the definition of CID trials and the role of DHSC.
What is a CID trial and why do them?
Professor Pam Kearns, Cancer Research UK Clinical Trials Unit and Institute of Genomic Sciences in Birmingham, explains what a CID trial is and why we should do them. You'll hear examples of what is meant by a CID trial, the benefits of this method and the challenges they pose.
What is the role of the Data Monitoring Committee in CID trials?
Louise Brown, Medical Research Council Clinical Trials Unit at University College London, explains what a Data Monitoring Committee does, why it is important and how it makes decisions about clinical trials.
Transparency and publication of finished CID trials arm data
Professor Pam Kearns, Cancer Research UK clinical trials unit and Institute of Genomic Sciences in Birmingham, discusses the transparency and publication of data when an arm in a CID trial closes.
What information is important to patients and their families?
Debbie Keatley, Independent Cancer Patients' Voice, discusses what information is important to patients and their families when considering taking part in a CID trial.
What do Research Ethics Committee (REC) members need to know about CID trials?
Stephanie Ellis, Chair of the Hampstead and Cambridge Central Ethics Committee, explains what ethics committee members need to know from applicants about CID trials.
How to write patient facing documents that make sense
Stephanie Ellis, Chair of the Hampstead and Cambridge Central Ethics Committee, and Debbie Keatley, Independent Cancer Patients' Voice, explain how to write patient facing documents and provide recommendations on how and when information should be presented for patients and their family.
CID Trials and HRA Approval
Will Navaie, HRA, explains about CID trials from the HRA's perspective.
The development of the consensus statement for the design and conduct of CID trials
Professor Sarah Blagden, University of Oxford, discusses the development of the paper for the British Journal of Cancer: Effective delivery of CID cancer trials.
Defining, designing and analysing CID trials
Catey Bunce, King's College London, explains the statistical challenges and opportunities of defining, designing and analysing CID trials.
Defining a platform trial and the advantages of using a platform trial design
Professor David Sebag-Montefiore, University of Leeds, discusses the definition of a platform trial in clinical oncology and its advantages.